Eli Lilly hedges for a GLP-1 revenue drop-off with $7B acquisition [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide. (Photo by Scott Olson/Getty Images) Scott Olson/Getty Images Eli Lilly acquired Kelonia , an in-vivo CAR-T technology company incubated by Venrock, for $3.25 billion in cash upfront and with a total payout of $7 billion if certain milestones are met. It's the latest signal of how Eli Lilly, like many of its peers, are using their substantial cash from the GLP-1 boom to diversify beyond the obesity market. It's also a nice exit for a biotech company whose last round was a Series A in 2022 at a $104 million post-money valuation, per PitchBook data. “M&A in 2026 feels pretty hot,” said Bryan Roberts, a Venrock partner who led the firm's investments in Kelonia. “The obesity wave is creating opportunity and cash flow — and fear about what happens post,” he added. Sign up for The Daily Pitch newsletter Subscribe Eli Lilly's combined revenue from GLP-1s hit $36.5 billi
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind [Seeking Alpha]Seeking Alpha
- Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal [Yahoo! Finance]Yahoo! Finance
- Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website